InvestSMART

EVE Health Group Limited (ASX:EVE)

ALERT: Price-sensitive ASX Announcement for EVE
Current share price for EVE : $0.017 -0.014 (-45.16%)+
Announcement
Release
29 Apr 2026 8:13AM
Price at Release
$0.031
Full Release
download
Summary
EVE Health Group Limited reported significant progress in its March 2026 quarterly update, highlighting the commercial launch of Libbo®, an oral dissolving film treatment for erectile dysfunction, in Australia. This launch was supported by the activation of a digital health platform, stiffissue.com, enabling end-to-end patient engagement. EVE also expanded its reformulation pipeline with new pharmaceutical candidates targeting sexual health and cardiovascular therapies. Financially, the company completed a $1.3 million capital placement to advance its pharmaceutical initiatives. The appointment of Dr. Sama Balasubramanian to the Scientific Advisory Board aims to strengthen EVE's strategic capabilities. The company reported stable customer receipts and outlined its outlook for continued development and commercialization of its pharmaceutical products.
Key Points
  • Commercial launch of Libbo® in Australia.
  • Activation of stiffissue.com platform.
  • Expansion of reformulation pipeline with new candidates.
  • Completion of a $1.3 million capital placement.
  • Appointment of Dr. Sama Balasubramanian.
  • Stable customer receipts and $0.25 million in the current quarter.
  • Outlook for continued commercialization and development.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.